• AMG 9810 TRPV1 Antagonist Workflows

  2026-09-10

  AMG 9810 provides a selective pharmacological handle for separating TRPV1-driven calcium entry and CGRP secretion from downstream sensory-cell effects. This guide combines practical calcium-imaging and CGRP workflows with a carefully bounded metabolic-stress extension inspired by AMPK–SQSTM1 research.

• Syringin and Sunitinib in Renal Cell Carcinoma

  2026-09-09

  The reference study identifies Syringin as a potential adjunct to sunitinib in renal cell carcinoma (RCC), linking reduced tumor-cell viability, migration, and survival to EGFR/PI3K/Akt pathway modulation. Its integrated use of network pharmacology, molecular docking, bioinformatics, cell assays, and Western blotting provides a mechanistic framework for studying sunitinib sensitivity, although the findings remain preclinical and require validation in additional models.

• A 83-01 (ALK inhibitor) for Reliable Cell Assays

  2026-09-09

  Learn how A 83-01 (ALK inhibitor), SKU A3133, can improve experimental interpretation in viability, proliferation, EMT, and organoid workflows by providing defined TGF-β/Smad pathway inhibition. This scenario-based guide covers mechanism, dosing, stock preparation, assay controls, data interpretation, and practical product-selection criteria.

• Meropenem Workflows for Carbapenem Resistance

  2026-09-08

  Build reproducible susceptibility, resistance, and transmission assays with Meropenem, a β-lactam antibiotic carbapenem designed for broad bacterial challenge studies. This workflow connects PBP inhibition to plasmid surveillance, helping researchers distinguish drug response from mobile carbapenemase-driven resistance.

• Taihangia rupestris Leaves: UPLC-MS/MS and Bioactivity

  2026-09-08

  This 2026 RSC Advances study combines UPLC-MS/MS chemical profiling with orthogonal antioxidant, α-glucosidase inhibition, affinity-screening, and molecular-docking approaches to compare wild and cultivated Taihangia rupestris leaves. Its central finding is that foothill cultivation can produce chemically richer, more active material than wild plants, supporting conservation-oriented sourcing while identifying candidate compounds for further antidiabetic research.

• Deracoxib Workflows for COX-2 Research

  2026-09-07

  Deracoxib supports exposure-aware inflammation assays, canine osteosarcoma viability studies, and combination-treatment screens. This guide translates reference findings into practical dosing, controls, troubleshooting steps, and decision points for separating COX-2 biology from nonspecific cytotoxicity.

• AMG 9810: TRPV1 Antagonism Under Stress

  2026-09-07

  AMG 9810 is a selective TRPV1 antagonist for dissecting calcium entry and neuropeptide signaling. This article develops a stress-aware assay framework that connects sensory neuron experiments with insights from AMPK–SQSTM1 metabolic-stress biology without conflating the two systems.

• Psoralen-Induced Cholestasis via ERK1/2

  2026-09-05

  Chen and colleagues showed that psoralen and isopsoralen, estrogen-like constituents of Psoraleae Fructus, induce cholestatic injury in zebrafish larvae while activating ERK1/2 and disrupting bile acid homeostasis. The study connects phytoestrogenic activity with ERK signaling and provides pharmacologic rescue evidence supporting ERK1/2 as a mechanistic target for further cholestasis research.

• Tamsulosin: α1A Mechanism and Research Uses

  2026-09-04

  Tamsulosin is a selective α1A-adrenergic receptor antagonist used to study smooth muscle relaxation, ureteral stone passage, and postoperative urinary retention. Product-dossier evidence reports improved stone expulsion, higher maximum urinary flow, and approximately 50% lower postoperative retention risk under specified clinical contexts.

• Metabolomics of Carbapenemase-Producing Enterobacterales

  2026-09-04

  The 2025 reference study uses LC-MS/MS metabolomics and machine learning to distinguish carbapenemase-producing from non-producing Enterobacterales through antibiotic-free metabolic signatures. Its findings connect resistance classification with altered cellular pathways and support the development of faster, phenotype-informed diagnostic workflows.

• Chemotherapy Enhances Neoantigen T Cell Therapy

  2026-09-03

  Sagie et al. identify a KRAS.G12V-specific T cell receptor and show that lymphodepleting chemotherapy improves neoantigen-directed T cell killing by increasing immunoproteasome activity and HLA-I expression. The study links chemotherapy-driven remodeling of the tumor immunopeptidome with stronger recognition by TCR-engineered cells, tumor-infiltrating lymphocytes, and T cell engagers.

• Melittin Workflows for GPCR and Apoptosis Research

  2026-09-03

  Melittin provides a practical way to perturb Gs- and Gi-linked signaling while pairing pathway measurements with viability, apoptosis, and migration assays. This workflow translates a glioblastoma lipid-signaling study into controlled experiments that distinguish G protein effects from nonspecific peptide-associated toxicity.

• Azathramycin A in Reliable Cell Assays

  2026-09-02

  A scenario-based guide to using Azathramycin A (SKU BA1060) in cell viability, proliferation, and Mycobacterium tuberculosis research workflows. It covers mechanism, solvent compatibility, stock preparation, assay controls, PK/PD interpretation, and practical supplier-selection criteria.

• PPARγ–STAT Signaling in DSS Colitis

  2026-09-02

  A study in a dextran sulfate sodium model of inflammatory bowel disease links PPARγ activation with macrophage polarization through reciprocal changes in STAT-1 and STAT-6 signaling. Its combined cell and mouse experiments suggest that this pathway can influence intestinal inflammation, barrier integrity, and tissue repair, while also highlighting limits on translating acute preclinical findings to human disease.

• Meropenem Workflows for Resistance Research

  2026-09-01

  Meropenem combines broad PBP-directed activity with practical value in susceptibility testing, time-kill experiments, resistance surveillance, and infection-model development. This workflow-focused guide shows how to improve assay reproducibility, compare free and nanoparticle formulations, and interpret resistance without confusing research findings with clinical treatment advice.

7613 records 1/508 page Next 12345 下5页 Last page